METHODS FOR PREDICTING GASTROINTESTINAL IMMUNE - RELATED ADVERSE EVENTS (GI-IRAE) IN PATIENTS TREATED WITH CO - STIMULATORY PATHWAY MODULATORS

摘要

The invention described herein relates to diagnostic and therapeutic methods and compositions useful for predicting the likelihood a cancer patient will experience a gastrointestinal immune-related adverse event (GI-irAE) after administration of a pharmaceutically acceptable amount of an activator of the immune system.